Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 39.07
DXCM's Cash to Debt is ranked higher than
66% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. DXCM: 39.07 )
Ranked among companies with meaningful Cash to Debt only.
DXCM' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 18.17 Max: No Debt
Current: 39.07
Equity to Asset 0.75
DXCM's Equity to Asset is ranked higher than
70% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DXCM: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
DXCM' s Equity to Asset Range Over the Past 10 Years
Min: -0.63  Med: 0.72 Max: 0.92
Current: 0.75
-0.63
0.92
F-Score: 6
Z-Score: 53.13
M-Score: -3.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -16.06
DXCM's Operating margin (%) is ranked lower than
58% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. DXCM: -16.06 )
Ranked among companies with meaningful Operating margin (%) only.
DXCM' s Operating margin (%) Range Over the Past 10 Years
Min: -2272.81  Med: -93.13 Max: -8.29
Current: -16.06
-2272.81
-8.29
Net-margin (%) -16.26
DXCM's Net-margin (%) is ranked lower than
58% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. DXCM: -16.26 )
Ranked among companies with meaningful Net-margin (%) only.
DXCM' s Net-margin (%) Range Over the Past 10 Years
Min: -2147.42  Med: -113.45 Max: -8.64
Current: -16.26
-2147.42
-8.64
ROE (%) -37.64
DXCM's ROE (%) is ranked lower than
69% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. DXCM: -37.64 )
Ranked among companies with meaningful ROE (%) only.
DXCM' s ROE (%) Range Over the Past 10 Years
Min: -60568.63  Med: -73.89 Max: -19.97
Current: -37.64
-60568.63
-19.97
ROA (%) -28.66
DXCM's ROA (%) is ranked lower than
68% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. DXCM: -28.66 )
Ranked among companies with meaningful ROA (%) only.
DXCM' s ROA (%) Range Over the Past 10 Years
Min: -117.86  Med: -68.09 Max: -14.59
Current: -28.66
-117.86
-14.59
ROC (Joel Greenblatt) (%) -92.31
DXCM's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. DXCM: -92.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DXCM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -886.64  Med: -583.04 Max: -50.89
Current: -92.31
-886.64
-50.89
Revenue Growth (3Y)(%) 43.80
DXCM's Revenue Growth (3Y)(%) is ranked higher than
96% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. DXCM: 43.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DXCM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 29.30 Max: 103.1
Current: 43.8
0
103.1
EBITDA Growth (3Y)(%) -35.00
DXCM's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. DXCM: -35.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DXCM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -27.70 Max: 0.6
Current: -35
0
0.6
EPS Growth (3Y)(%) -24.10
DXCM's EPS Growth (3Y)(%) is ranked lower than
76% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. DXCM: -24.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DXCM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -40  Med: -24.10 Max: 47.3
Current: -24.1
-40
47.3
» DXCM's 10-Y Financials

Financials (Next Earnings Date: 2016-02-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

DXCM Guru Trades in Q1 2015

Joel Greenblatt Sold Out
Ron Baron 1,338,407 sh (-0.17%)
Mario Gabelli 50,800 sh (-1.55%)
RS Investment Management 354,260 sh (-33.81%)
Jim Simons 69,343 sh (-74.25%)
» More
Q2 2015

DXCM Guru Trades in Q2 2015

RS Investment Management 573,480 sh (+61.88%)
Mario Gabelli 50,800 sh (unchged)
Ron Baron 1,337,607 sh (-0.06%)
Jim Simons 26,900 sh (-61.21%)
» More
Q3 2015

DXCM Guru Trades in Q3 2015

Paul Tudor Jones 9,851 sh (New)
Jim Simons 136,643 sh (+407.97%)
RS Investment Management 732,430 sh (+27.72%)
Ron Baron 1,330,742 sh (-0.51%)
Mario Gabelli 45,400 sh (-10.63%)
» More
Q4 2015

DXCM Guru Trades in Q4 2015

Mario Gabelli 44,400 sh (-2.20%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on DexCom Inc

Baron Funds Comments on DexCom Inc. - Jan 14, 2016

Another health care holding, DexCom, Inc., (NASDAQ:DXCM) sells a continuous glucose monitoring system for diabetics. Although this is an unusual investment for the portfolio because of its extended trading multiple, we think DexCom’s fundamentals justify our investment. Over the last three years, DexCom has launched a series of new products driving a dramatic acceleration in revenue growth. We believe the company’s new product pipeline remains robust and will lead to further adoption among the growing population of diabetics.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on DexCom Inc. - Aug 19, 2015

DexCom, Inc. (NASDAQ:DXCM) sells a continuous glucose monitoring device for insulin dependent diabetes. DexCom reported very strong results. Revenues grew 55% in the quarter, and the company reiterated guidance for continued exceptional growth. The company launched its “share” system, which allows parents or spouses to receive the users’ blood glucose data from the users’ handheld devices, an important new feature. And they filed for approval of their next generation offering that will transmit data directly to a smartphone, eliminating the need to carry a receiver. Strong new patient starts, more accurate and feature rich products, and an expanding addressable market make for a company that, we believe, can grow rapidly for a considerable time go forward.



From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about DexCom Inc

Baron Funds Comments on DexCom Inc. Guru stock highlight
Another health care holding, DexCom, Inc., (NASDAQ:DXCM) sells a continuous glucose monitoring system for diabetics. Although this is an unusual investment for the portfolio because of its extended trading multiple, we think DexCom’s fundamentals justify our investment. Over the last three years, DexCom has launched a series of new products driving a dramatic acceleration in revenue growth. We believe the company’s new product pipeline remains robust and will lead to further adoption among the growing population of diabetics. Read more...
Top Weekly Insider Sells Highlights DexCom, Gilead Sciences, Palo Alto Networks, Salesforce.com lead the way
According to GuruFocus Insider Data, the largest insider sells during the past week were DexCom Inc. (NASDAQ:DXCM), Gilead Sciences Inc. (NASDAQ:GILD), Palo Alto Networks Inc. (NYSE:PANW) and Salesforce.com Inc. (NYSE:CRM). Read more...
Weekly CFO Sells Highlight: Gilead Sciences, DexCom, and Palo Alto Networks Gilead CFO sells 6,250 shares of the company
According to GuruFocus Insider Data, the recent CFO sales were: Gilead Sciences Inc. (NASDAQ:GILD), DexCom Inc. (NASDAQ:DXCM), and Palo Alto Networks Inc. (NYSE:PANW). Read more...
Baron Funds Comments on DexCom Inc.
DexCom, Inc. (NASDAQ:DXCM) sells a continuous glucose monitoring device for insulin dependent diabetes. DexCom reported very strong results. Revenues grew 55% in the quarter, and the company reiterated guidance for continued exceptional growth. The company launched its “share” system, which allows parents or spouses to receive the users’ blood glucose data from the users’ handheld devices, an important new feature. And they filed for approval of their next generation offering that will transmit data directly to a smartphone, eliminating the need to carry a receiver. Strong new patient starts, more accurate and feature rich products, and an expanding addressable market make for a company that, we believe, can grow rapidly for a considerable time go forward. Read more...

Ratios

vs
industry
vs
history
Forward P/E 63.69
DXCM's Forward P/E is ranked lower than
92% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.38 vs. DXCM: 63.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 22.41
DXCM's P/B is ranked lower than
99.99% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. DXCM: 22.41 )
Ranked among companies with meaningful P/B only.
DXCM' s P/B Range Over the Past 10 Years
Min: 3.88  Med: 15.71 Max: 209.25
Current: 22.41
3.88
209.25
P/S 11.79
DXCM's P/S is ranked lower than
100% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. DXCM: 11.79 )
Ranked among companies with meaningful P/S only.
DXCM' s P/S Range Over the Past 10 Years
Min: 6.36  Med: 15.54 Max: 1058.5
Current: 11.79
6.36
1058.5
PFCF 213.52
DXCM's PFCF is ranked lower than
96% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.13 vs. DXCM: 213.52 )
Ranked among companies with meaningful PFCF only.
DXCM' s PFCF Range Over the Past 10 Years
Min: 213.52  Med: 500.25 Max: 753.29
Current: 213.52
213.52
753.29
POCF 92.06
DXCM's POCF is ranked lower than
93% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.16 vs. DXCM: 92.06 )
Ranked among companies with meaningful POCF only.
DXCM' s POCF Range Over the Past 10 Years
Min: 92.06  Med: 180.36 Max: 1503.33
Current: 92.06
92.06
1503.33
Current Ratio 3.46
DXCM's Current Ratio is ranked higher than
58% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. DXCM: 3.46 )
Ranked among companies with meaningful Current Ratio only.
DXCM' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 4.40 Max: 23.47
Current: 3.46
1.96
23.47
Quick Ratio 2.94
DXCM's Quick Ratio is ranked higher than
58% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. DXCM: 2.94 )
Ranked among companies with meaningful Quick Ratio only.
DXCM' s Quick Ratio Range Over the Past 10 Years
Min: 1.82  Med: 3.94 Max: 23.47
Current: 2.94
1.82
23.47
Days Inventory 68.17
DXCM's Days Inventory is ranked higher than
59% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. DXCM: 68.17 )
Ranked among companies with meaningful Days Inventory only.
DXCM' s Days Inventory Range Over the Past 10 Years
Min: 23.53  Med: 49.97 Max: 73.69
Current: 68.17
23.53
73.69
Days Sales Outstanding 57.29
DXCM's Days Sales Outstanding is ranked higher than
59% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. DXCM: 57.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.96  Med: 50.07 Max: 71.25
Current: 57.29
16.96
71.25
Days Payable 55.97
DXCM's Days Payable is ranked higher than
55% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. DXCM: 55.97 )
Ranked among companies with meaningful Days Payable only.
DXCM' s Days Payable Range Over the Past 10 Years
Min: 21.26  Med: 26.71 Max: 43.91
Current: 55.97
21.26
43.91

Valuation & Return

vs
industry
vs
history
Price/Net Cash 87.51
DXCM's Price/Net Cash is ranked lower than
96% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.09 vs. DXCM: 87.51 )
Ranked among companies with meaningful Price/Net Cash only.
DXCM' s Price/Net Cash Range Over the Past 10 Years
Min: 4.94  Med: 33.03 Max: 166
Current: 87.51
4.94
166
Price/Net Current Asset Value 30.86
DXCM's Price/Net Current Asset Value is ranked lower than
90% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.70 vs. DXCM: 30.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DXCM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.88  Med: 19.47 Max: 53.03
Current: 30.86
4.88
53.03
Price/Tangible Book 23.21
DXCM's Price/Tangible Book is ranked lower than
91% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.71 vs. DXCM: 23.21 )
Ranked among companies with meaningful Price/Tangible Book only.
DXCM' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.7  Med: 14.12 Max: 154.75
Current: 23.21
4.7
154.75
Price/Median PS Value 0.76
DXCM's Price/Median PS Value is ranked higher than
67% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.95 vs. DXCM: 0.76 )
Ranked among companies with meaningful Price/Median PS Value only.
DXCM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 0.99 Max: 43.81
Current: 0.76
0.52
43.81
Earnings Yield (Greenblatt) (%) -1.36
DXCM's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. DXCM: -1.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DXCM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.37  Med: 0.00 Max: 0
Current: -1.36
-1.37
0

More Statistics

Revenue(Mil) $356
EPS $ -0.73
Beta0.25
Short Percentage of Float2.58%
52-Week Range $47.92 - 103.29
Shares Outstanding(Mil)81.29

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 394 561 751 1,017
EPS($) -0.36 0.04 0.84 1.53
EPS without NRI($) -0.36 0.04 0.84 1.53

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:DC4.Germany,
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company's SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
Baron Funds Comments on DexCom Inc. Jan 14 2016 
Investing for Lower Risk Long-Term Growth in a Volatile Asset Class - Baron Funds Winter Newsletter Jan 14 2016 
Top Weekly Insider Sells Highlights Sep 15 2015 
Weekly CFO Sells Highlight: Gilead Sciences, DexCom, and Palo Alto Networks Sep 13 2015 
Panic-Proofing the Small Investor Aug 26 2015 
Baron Funds Comments on DexCom Inc. Aug 19 2015 
Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc. Jul 20 2015 
Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM Jul 14 2015 
Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc. Jul 13 2015 
Dexcom’s Smart Glucose Monitoring System Receives FDA Approval Jan 27 2015 

More From Other Websites
UPDATED PRESENTATION TIME: DexCom Announces Upcoming Conference Presentation Feb 09 2016
Dexcom downgraded by Robert W. Baird Feb 08 2016
DEXCOM INC Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 04 2016
DexCom Announces Upcoming Conference Presentation Jan 29 2016
DexCom Announces Upcoming Conference Presentation Jan 29 2016
Big Pharma's bet on Big Data creates opportunities and risks Jan 26 2016
Big Pharma's bet on Big Data creates opportunities and risks Jan 26 2016
Big Pharma's bet on Big Data creates opportunities and risks Jan 26 2016
DexCom Schedules Fourth Quarter and Full Year 2015 Earnings Release and Conference Call for February... Jan 22 2016
DexCom Schedules Fourth Quarter and Full Year 2015 Earnings Release and Conference Call for February... Jan 22 2016
DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition Jan 12 2016
DexCom Announces Upcoming Conference Presentation Jan 04 2016
DexCom Announces Upcoming Conference Presentation Jan 04 2016
Insight - Beyond Fitbit: The quest to develop medical-grade wearables Dec 18 2015
DexCom, Inc. breached its 50 day moving average in a Bearish Manner : December 14, 2015 Dec 14 2015
DEXCOM INC Financials Dec 08 2015
Is Plum Creek Timber Co. Inc. (PCL) Going to Burn These Hedge Funds? Nov 27 2015
DexCom, Inc. breached its 50 day moving average in a Bullish Manner : November 23, 2015 Nov 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK